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Abstract
A fundamental model of tumor growth in the presence of cytotoxic chemother-
apeutic agents is formulated. The model allows to study the role of the Norton-
Simon hypothesis in the context of dose-dense chemotherapy. Dose-dense pro-
tocols aim at reducing the period between courses of chemotherapy from three
weeks to two weeks, in order to avoid tumor regrowth between cycles. We ad-
dress the conditions under which these protocols might be more or less beneficial
in comparison to less dense settings, depending on the sensitivity of the tumor
cells to the cytotoxic drugs. The effects of varying other parameters of the pro-
tocol, as for example the duration of each continuous drug infusion, are also in-
spected. We believe that the present model might serve as a foundation for the
development of more sophisticated models for cancer chemotherapy.
1. Introduction
Improvements in chemotherapy mainly depend upon minimizing the toxic
side-effects of drugs on healthy tissues and tackling the resistance of cancer cells
to such medications [1, 2]. Nevertheless, randomized trials carried out along the
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last half century have proved that the specific arrangement of protocols is of rel-
evance as well [3–5]. In particular, breast cancer trials have revealed that re-
ducing the period between cycles of chemotherapy from three to two weeks in-
troduce moderate but statistically significant benefits in disease free survival at
five years and overall survival [6]. Surprisingly, this can be achieved without in-
troducing higher toxicities with the aid of granulocyte colony-stimulating factor.
This increase in the frequency of drug administration has been termed dose-dense
chemotherapy, because when the dose is represented against time, these protocols
look more dense [7].
Despite recent success in adjuvant chemotherapy for breast cancer [8], the
benefits of dose-dense chemotherapy are not undoubted [9]. Remarkably, the ap-
pearance of these protocols for the treatment of solid tumors has posed fundamen-
tal questions concerning the nature of solid tumor growth. Moreover, it has also
suggested a theory of tumor growth for breast cancer, based on the concept of
self-metastasis [7, 10]. In particular, the Norton-Simon hypothesis has been sug-
gested as a possible explanation to its beneficial properties. This hypothesis states
that the rate of destruction by chemotherapy is proportional to the rate of growth
of the unperturbed tumor [11]. As has been recently suggested, the concept of
dose-density might be pertinent even in the absence of any hypothesis affecting
the particular nature of the growth of the tumor [12].
Concerning previous modelling efforts on this topic, some preliminary dis-
cussion is deserved. Several deterministic and stochastic models have appeared
in the literature over the last decades to describe different phenomena related to
dose-dense chemotherapy and protocol optimization [13–18]. However, some of
these works do not model cell kill [13], while others model it in an indirect way,
by imposing conditions on the decay of the tumor once the drugs have been ad-
ministered [14]. On the other hand, to the best of our knowledge, those works
that explicitly model cell kill and consider the Norton-Simon hypothesis always
assume a linear dependence between the rate of cell destruction and the dose of
drug delivered [15, 16]. This assumption leads to dose-response curves which are
linear when plotted on a log scale. These curves, as has been demonstrated, do
not fit properly data from solid tumors [19].
In the present work we propose an ordinary differential equation (ODE) model
for nonlinear cancer chemotherapy to investigate under which conditions dose-
dense protocols are more or less advantageous. It is not our purpose to develop
specific protocols for a certain class of tumors, but rather to find general guiding
principles which might aid clinicians to bias their decisions in the design of better
protocols in the future. Special attention is paid to the relative possible benefits
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of dose-dense protocols compared to more dose-intense ones. Although dose-
intensity is commonly defined as an average over the whole treatment in the field
of oncology, we use it hereafter to deem an increase of the total dose administered
per cycle [12].
2. Model description
2.1. Tumor growth in the presence of chemotherapeutic drugs
A general multicompartmentmodel for cancer chemotherapy can be built from
previous modeling works [16, 20–24]. Since the cell cycle comprises four phases
(mitosis, gap 1, synthesis and gap 2) and cells can also be quiescent (gap 0), a
possible modeling framework should consider five different compartments rep-
resenting the cell populations in each of them. In principle, the use of different
compartments is relevant since some drugs only destroy cells on a specific phase
of the cell cycle [25, 26]. However, in practice, one or more compartments can
be joined into a single compartment, reducing the dimensionality of the problem.
For example, if there is only one cycle specific drug, a model with three compart-
ments can be devised. Firstly, two compartments would be required to distinguish
between mitotic and quiescent cells. Then, the cycling cells should be subdivided
among those cells which are in the particular phase in which the cycle specific
drugs exert their effect, and those that are in the complementary part of the cell
cycle.
We begin with the most simple model example capable of representing the
Norton-Simon hypothesis. Thus, in this first approach, we are only interested in
the effects of just one cycle non-specific (CNS) drug and, therefore, we restrict
ourselves to a single compartment of mitotic tumor cells P (t). Accordingly, we
also gather in a single compartment the mitotic and the quiescent cells, and use a
single function γ(P ) to represent the net result of proliferation and death of tumor
cells due to necrosis and apoptosis. The drug concentration is represented as C(t).
Therefore, we study the differential equation
dP
dt
= γ(P )P − κ(P,C)P. (1)
Because a somatic cell divides through mitosis, the growth of a cell population
is at most geometric [27]. This suggests that γ(P ) should be a monotonically
decreasing function of P . We illustrate most of our analysis using γ(P ) = r(1−
P/K), which corresponds to a logistic growth [28–30], even though Gompertzian
growth γ(P ) = r log(K/P ) is tested as well [31].
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The design of the function κ(P,C) is more delicate, since we want the model
to be capable of reproducing the Norton-Simon hypothesis. We start from the
Exponential-Kill model, which has been tested using in vitro and in vivo data
[19, 32]. The fractional cell kill is represented in such model by a term b(1−e−ρC),
where b represents the maximum fractional cell kill and ρ is commonly referred
in the literature as the resistance of the tumor cells to the drugs [12, 19]. How-
ever, resistance is a complex evolutionary process involving several biological
mechanisms, as for example the drug efflux through transmembrane proteins or
DNA-damage repair mechanisms [33]. Hence, those models that incorporate tu-
mor resistance to chemotherapeutic drugs traditionally make use of several com-
partments [14, 15] consisting of cells with different values of ρ. Therefore, we
shall call the parameter ρ the sensitivity, hereafter. More precisely, ρ is directly
proportional to the sensitivity. In the present work we investigate rather homo-
geneous tumors consisting of cells whose deviations in this parameter from the
average value is very small. In summary, we can consider a nonlinear separable
function in the form κ(P,C) = h(P )b(1− e−ρC). It is important to note that this
new fractional cell kill saturates for increasing values of the drug concentration, a
feature frequently overlooked in models of chemotherapy for solid tumors, which
mainly consider a linear dependence on the drug concentration [15, 16].
Now we recall that, according to the Norton-Simon hypothesis, the rate of
destruction of the tumor is proportional to the rate of growth of the the same
unperturbed tumor. Here, we take this statement in a non-strict sense, since we
have not found experimental evidence of a direct proportionality h(P ) ∝ γ(P ).
Quite the opposite, there is evidence that CNS drugs act to some extent on the
quiescent compartment as well [22, 34], which contradicts such direct relation of
proportionality. Nevertheless, it is likely that cells inside a solid tumor are less
susceptible to chemotherapeutic drugs. This might be a consequence of the fact
that the concentration of drugs attenuates as they penetrate inside a solid tumor,
since they are absorbed by the outmost external cells. Note also that cells in the
interior are less exposed as well and that the cells on the boundary of a tumor are
more actively proliferating than the cells in its core [35, 36]. Hence, as previ-
ously stated, we believe that it is enough to assume that the fractional cell kill of
chemotherapeutic drugs decreases for bigger tumors.
In conclusion, we assume that h(P ) is a monotonically decreasing function of
the cell population P . More specifically, we consider a Holling type II functional
response [37] in the form
h(P ) =
rK
K + sP
. (2)
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This particular choice can be justified on the following grounds:
(a) The maximum rate of cell kill is proportional to the maximum growth rate of
the tumor.
(b) The fractional cell kill is smaller as the tumor gets close to the carrying ca-
pacity. The maximum value at the carrying capacity is r/(1 + s). Therefore,
the parameter s controls the Norton-Simon hypothesis, being both in a direct
relation.
(c) For s = 0 or K → ∞ we obtain the fractional cell kill used in [19]. In fact,
if both conditions hold, the model itself is the one used in such reference.
This situation corresponds to an exponentially growing tumor for which the
Norton-Simon hypothesis establishes that the rate of destruction should be
exponential.
(d) The action of some cytotoxic drugs resembles enzyme kinetics, where the
drug plays the role of the enzyme and the cell resembles to the substrate (e.g.
the alkylating agent Cisplatin binds to the cell DNA causing intrastrand cross-
links that ultimately can lead to apoptosis).
(e) In the limit of small concentrations or low sensitivity, the term 1−e−ρC can be
approximated as ρC. In this limit the function κ(P,C) obeys the Michaelis-
Menten kinetics, which has been extensively used in previous studies [21, 23].
Nevertheless, other functional responses will be tested, which allow to repre-
sent the Norton-Simon effect in its more strict formulation. But, unless otherwise
specified, we shall utilize the nonlinear ODE model
dP
dt
= r
(
1−
P
K
)
P − rb
K
K + sP
(
1− e−ρC
)
P, (3)
throughout the following sections.
2.2. Pharmacokinetics and protocols of chemotherapy
It remains to be introduced the pharmacokinetics of the model, which governs
the dynamics of the concentration of drug at the tumor site C(t). As in previous
works [21, 32, 38], we consider a one-compartment model and first order pharma-
cokinetics, which in some situations can be used as a good approximation in the
clinical practice [39]. The differential equation governing the concentration of the
drug is
dC
dt
= I(t)− kC(t), (4)
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Figure 1: A protocol of chemotherapy. The continuous infusion of two drugs (red and blue)
delivered with a period T of three weeks and using different doses D. The time duration of each
infusion ta differs for the two drugs as well.
where I(t) is the function representing the rate of flow of drug into the body (the
instantaneous dose-intensity) and k is the rate of elimination of the drug from the
bloodstream, from which the half-life can be computed as (loge 2)/k.
Concerning the drug delivery, we assume that the drug is administered intra-
venously at constant speed during a time ta in cycles of period T . Thus, a typical
protocol of chemotherapy can be schematically represented as in Fig. 1. If the
dose of drug given in a course of chemotherapy isD, then the instantaneous dose-
intensity I(t) is expressed mathematically as
I(t) =


D
ta
for t(mod T ) ∈ [0, ta)
0 for t(mod T ) ∈ [ta, T )
. (5)
The solution to equation (4) with a drug input given by equation (5), when a
number of N chemotherapeutic cycles have been delivered, yields
C(t) =


D
kta
(1− e−kt) + aN (t) for t(mod T ) ∈ [0, ta)
D
kta
(ekta − 1)e−kt + aN(t) for t(mod T ) ∈ [ta, T )
, (6)
where aN (t) represents the decaying accumulated concentration of drug during
the N + 1-th cycle of chemotherapy. This function equals zero during the first
cycle (a0(t) = 0) and it is equal to
aN(t) =
D
kta
(ekta − 1)e−kt
N∑
n=1
e−nkT , (7)
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Figure 2: The drug concentration. The time series of the drug concentration for five cycles of
chemotherapy administered every T weeks. Each course of chemotherapy consists of a continuous
infusion of drug that lasts a time ta. Hence the rate of infusion is D/ta. The constant rate of
elimination of the drug from the bloodstream is k. Asymptotically, a steady oscillation between
two values of the concentration Cmins and C
max
s is attained.
for the subsequent cycles. Using this equation, it can be easily demonstrated that
when the number of cycles N tends to infinity, the concentration reaches a steady
oscillation Cs(t) between a minimum value
Cmins =
D
kta
ekta − 1
ekT − 1
, (8)
and a maximum value Cmaxs = C
min
s e
k(T−ta). This periodicity is represented
in Fig. 2. Since the periodicity of the cycles of chemotherapy commonly spans
several weeks, whereas the drug is eliminated rather quickly (days) in comparison,
the accumulation of drug is not usually very important, unless ta is close to T .
3. High continuous doses
To prepare our intuition for the numerical results that are presented in the fol-
lowing section, we first study the parameter space in the case that of tumors which
are highly sensitive (ρ → ∞) to the drug, which is continuously administered at
sufficiently high doses (D 9 0). If this holds, we can take the limit ρC →∞ and
the differential equation (3) can be simplified to
dx
dτ
= (1− x) x−
b
1 + sx
x, (9)
where the dimensionless variables x = P/K and τ = rt have been introduced.
This differential equation possess one, two or three fixed points, depending on the
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Figure 3: The parameter set. When the drugs are given at high doses for long periods of time,
four different regions can be distinguished according to the asymptotic dynamics. In region I the
therapy is not effective and the tumor is just reduced in size, but not eliminated. The regions II
and III represent parameter values for which the tumor is surely destroyed. The cyan region is
separated from the dark blue region by the dashed line, because it presents two more fixed points.
However, they occur for negative values of the cell population, which have no biological meaning.
In region IV the tumor can be eradicated or not depending on its size at the beginning of the
treatment.
values of the parameters b and s. The fixed point x∗ = 0 is always present, while
the others are the solution to the quadratic equation (1 − x)(1 + sx) − b = 0,
whose discriminant equals to (s − 1)2 − 4s(b − 1). As shown in Fig. 3, b < 1
defines region I, in which there always exist two fixed points. The origin is a
repelling fixed point, whereas the remaining point is an attractor representing a
tumor that exists bellow its carrying capacity. Consequently, if the drug is not
effective enough, the tumor can not be destroyed, even if the drugs are delivered
continuously and forever. The remaining part of the parameter space is subdivided
into three smaller regions (II, III and IV) by the curve b = 1+ (s− 1)2/(4s). The
upper and left blue regions delimited by this curve (regions II and III) represent a
domain for which there is only one positive attracting fixed point x∗ = 0. In this
case, the tumor can be asymptotically destroyed by the chemotherapeutic drugs.
The only difference between regions II and III is that the latter has two more fixed
points. However, they occur for negative values of the cell population, which are
biologically meaningless. Finally, when we go from region III to region IV, two
fixed points are born through a saddle-node bifurcation. Two of them are attrac-
tors, one at x∗ = 0 and another existing bellow the carrying capacity, separated by
a repelling fixed point. Therefore, the tumor can be destroyed or not, depending
on its size at the beginning of the treatment.
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Figure 4: Investigated protocols. (p1) A reference protocol consisting on a continuous infusion
of a dose of a single drug delivered every three weeks through intravenous bolus. (p2) A more
dose-intense protocol for which the dose of drug per course is multiplied by three. (p3) A more
dose-dense protocol for which the period between cycles is divided by three. (p4) A protocol for
which the same dose of drug is delivered, but through longer lasting infusions.
4. Numerical simulations
In the present section we accomplish a comparative study between several
types of chemotherapeutic protocols. For this purpose, we solve equation (3) with
a drug concentration given by equation (6) for four different protocols, which are
represented in Fig. 4, and two sensitivity scenarios. The high sensitivity scenario
corresponds to a value ρ = 1.0 mg−1, while the low sensitivity scenario is given
by ρ = 0.01 mg−1, which are within extreme values appearing in [19]. We use
as a reference a protocol (p1) with parameter values T = 3 weeks, ta = 1 min
and D = 60 mg, which are typical for locally advanced breast cancer1. A second
protocol (p2) is considered that it is three times more dose-intense, with D =
180 mg. This increase in the dose is chosen bearing in mind that the dependence
of the fractional cell kill on the drug concentration is exponential. Therefore,
this variation suffices for our purposes. Nevertheless, we note that in practice
there is a great variability concerning the values of ρ and D among the different
drugs and protocols [19]. The third protocol (p3) is more dose-dense than the first
protocol, with T = 1 week. Although protocols that are more dose-dense that
two weeks are unrealistic, we have decided to push dose-density to the smallest
1Information about standard protocols of chemotherapy has been drawn from
http://www.bccancer.bc.ca/health-professionals/clinical-resources/chemotherapy-protocols
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Figure 5: Time series. The evolution of a tumor cell population (red) under the action of
chemotherapy (blue) for a dose of drug D = 60 mg injected as a bolus (ta = 1 min). The
parameter values characterizing the cytotoxicity are ρ = 0.1mg−1, s = 4.1 and b = 3.6 weeks−1.
The concentration of drug is plotted for clarity, disregarding its specific values. (a) A dense pro-
tocol with a period T of one week. The survival fraction of tumor cells at the minimum of the
treatment (nadir) is σ = P (tnad)/P (0) = 0.61. (b) A less dense protocol with a period T of three
weeks. The survival fraction of tumor cells at the nadir is σ = 0.84. Note that in this case the nadir
is reached at the beginning of the treatment, while in the previous case the tumor is progressively
reduced.
values as possible, to have as a reference a situation which is limiting in the time
scale commonly considered (weeks). A final fourth protocol (p4) tests the effect of
increasing the duration of the infusion up to half a week ta = 0.5 weeks, keeping
the total dose per course constant.
To investigate the relative benefits of each protocol, we compute the survival
fraction of tumor cells at the nadir σ = Pnad/P0 of the treatment. This effective-
ness criterion has been adopted in previous works [22]. Consequently, we recall
that, since in this first study we are not explicitly modelling toxicity, the benefits
or the effectiveness of a protocol should not be read from a clinical point of view,
but instead from a theoretical one. Then, we represent it in the parameter space
(b, s), as in the previous section. More specifically, we represent in logarithmic
scale the ratio between survival fractions at the nadir σi/σj for a pair (pi and pj)
of protocols. Therefore, when protocol pi is more beneficial than protocol pj we
have log(σi/σj) < 0, since σ is always smaller than one. Oppositely, it will be
higher or equal than zero when pi is less beneficial than protocol pj .
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Unless otherwise specified, the simulations are carried out considering a tumor
whose maximum rate of growth is r = 0.8 weeks−1 and with a value of the
carrying capacity ofK = 109 cells [32]. An extremely fast growing tumor would
be one in which all cells were ceaselessly dividing through mitosis. Since the
cell cycle of a human cell lasts approximately one day, this corresponds to an
exponentially growing tumor with a constant rate value of r = 4.85 weeks−1.
Therefore, we are considering a quite aggressive tumor. The carrying capacity
corresponds to a detectable tumor mass of approximately one gram. The original
size of the tumor is considered to be P0 = 9 · 10
8 cells. We take a typical value
of k = 4.85 weeks−1, which corresponds to a half-life of approximately one day
[12]. Two typical trajectories for the parameter values ρ = 0.1 mg−1, s = 4.1 and
b = 3.6 weeks−1 are shown in Fig. 5. They illustrate a situation suggesting the
possible benefits of dose-dense protocols.
4.1. High sensitivity scenario
Obviously, when the sensitivity to the drugs is high, we see that increasing
the dose delivered or the frequency of the cycles three times is beneficial for all
parameter values. This is shown in Fig. 6, where the survival fraction at the nadir
of the treatment is represented in the parameter space. Thus, mathematically,
increasing the frequency of the cycles and the dose of drug are both convenient.
However, as can be seen in Fig. 6(b), if the drugs are very effective destroying
the tumor cells (high values of b), the benefits of increasing dose-density (the
frequency) are very small (σ1/σ3 close to one). The reason that explains this
behavior is that if the cell population is severely reduced, then the regrowth of the
tumor cells is comparatively small. This does not occur for an increase in the dose-
intensity (see Fig. 6(a)), although increasing too much the dose might introduce an
intolerable toxicity. Consequently, the relative benefits of increasing three times
the dose, compared to an identical increase in the frequency of administration, are
higher for small values of s and high values of b. This is shown in Fig. 6(d), where
we clearly see that σ2 is smaller than σ3 for such values of b.
We also see in the same figure that as we increase s, dose-densification be-
comes more pertinent. Indeed, the Norton-Simon hypothesis strengthens the im-
portance of dose-density. Ultimately, an increase in the duration of the infusion
to half a week, maintaining constant the dose and the periodicity, seems to be the
most beneficial in our model (see Figs. 6(e) and (f)). In part this occurs because
the drug is acting more time on the tumor, avoiding the regrowth between cycles.
However, it must be noted that the peak of drug concentration is smaller. There-
fore, it is expected that this is true only for tumors which are very sensitive to
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the drugs and when these drugs are administered at sufficiently high doses. Fur-
thermore, this is somewhat equivalent to deliver drugs continuously at doses that
are smaller than the standard, which in many situations can be more toxic and
ineffective [40].
4.2. Low sensitivity scenario
Now we turn our attention to a situation in which the sensitivity of the tumor
cells to the drugs is low. In this case the scenario changes dramatically and be-
comes less rich. Firstly, in Fig. 7 we observe that the effects of increasing the dose
of drug or the frequency are in general much smaller. More importantly, increas-
ing the dose three times is now more convenient than increasing dose-density by
the same amount for all the values of the parameters b and s. As can be seen in
Fig. 7(c), σ3 > σ2 everywhere in the parameter space. This result can be inter-
preted as follows. If the sensitivity of the tumor cells to the drugs is very low, the
more dose of drug we give, the more chances for a tumor cell to be lethally hit
by these drugs. Consequently, if the drugs are not causing substantial destruction,
increasing the frequency does not introduce significant advantages. For the same
reason, we see in Fig. 7(d) that increasing the time of drug infusion is now harm-
ful, except for drugs that are very destructive in the absence of the Norton-Simon
effect.
4.3. Testing the robustness of our results
We have tested the effect of modifying the parameters that represent the carry-
ing capacity K and the rate of elimination of the drug k. Increasing the carrying
capacity one thousand times (which approximately corresponds to a tumor of one
kilogram) does not alter substantially the conclusions. Now the growth of the tu-
mor approximates to exponential and the model is exactly the same as the one pre-
sented in [19]. Mathematically, this can be written as γ(P )→ r and h(P )→ rb.
Consequently, the parameter s loses its importance and the graphics are similar to
the ones appearing in Fig. 6 for small values of s. Increasing four times the value
of k, which reduces the half-life to six hours, introduces two main effects. Firstly,
the drugs spend less time in the organism and therefore the impact of chemother-
apy is reduced. This enhances the importance of dose-density. The convenience
of increasing the frequency over increasing the dose for highly sensitive tumors is
more noticeable. Secondly, and for the same reason, the benefits of increasing the
time of infusion are higher for the high sensitivity case.
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Figure 6: Highly sensitive tumors (ρ = 1.0 mg−1). The fraction of cells that have survived the
treatment σi = P (tnad)/P (0) at the time tnad when the tumor reaches its minimum size (nadir)
is computed for each protocol pi. Then the same computation is repeated for a 300× 300 square
grid of values in the parameter set (s, b). Finally, the relative destruction between two protocols
pi and pj is represented in the parameter space by computing the natural logarithm (for which the
results are the most clear) of the quotient σi/σj (color bar). If log(σi/σj) > 0 in the color bar, the
protocol pj is better than protocol pi. (a) The effects of increasing the dose represented by σ1/σ2,
which is always beneficial. (b) The case σ1/σ3 representing an increase in dose-density, which
is beneficial for all parameter values. (c) Longer continuous infusions are studied by computing
σ1/σ4, which is the most beneficial. (d) Dose-intensity versus dose-density is studied by comput-
ing σ2/σ3. Depending on the parameter values one strategy is better than the other. (e) The values
of σ4/σ3, comparing an increase in dose-intensity against an increase in the time of infusion. (f)
The case σ2/σ4 shows that a sufficient increase in the duration of infusion is better that increasing
the dose-intensity.
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4.4. Other functional forms
To conclude our study, we have also tested the robustness of our results by
modifying the functional form of the growth term γ(P ). If we consider the
Gompertz differential equation, then we have γ(P ) = r log(K/P ). We keep
the same value of the carrying capacity K = 109 cells but modify the parame-
ter r = 0.12 weeks−1. This value is chosen so that two tumors, one following
Gompertzian growth and another growing logistically, reach a size of half of its
maximum valueK at the same time.
As can be seen in Fig. 8(a), under these conditions, the Gompertzian growth
is less steep than the logistic. If we compare P˙ for the two types of growth and
the parameters given, we see that the regrowth of the tumors between cycles is
smaller for the Gompertz case, except for very small cell populations P . Con-
sequently, and as depicted in Fig. 8(b), the benefits of trebling the dose-density
relative to augmenting the dose three times are in general smaller. Nevertheless,
we insist that increasing the dose and the frequency are still advantageous for both
scenarios. It is remarkable that for small values of s, dose-density prevails over
dose-intensity. As previously said, this is a consequence of the fact that for small
values of the cell populations and the parameter values used in the simulation, the
regrowth is greater for the Gompertz case. Anyway, this should not be read as
a failure of the Norton-Simon hypothesis, since the same stands for sufficiently
high values of s.
Finally, we have also inspected the effects of modifying h(P ), which we recall
that models the Norton-Simon effect. In particular, we have considered the case
h(P ) = r(1−sP/K). For s = 1, we obtain a direct proportionality between h(P )
and γ(P ), which represents the most rigorous form of the effect. No substantial
changes have been found in this case, except a less sensitivity to the parameter s,
similar to the one described two paragraphs above.
5. Concluding Remarks
In the present work we have studied the relative benefits of dose-dense proto-
cols and the role of the Norton-Simon hypothesis in nonlinear cancer chemother-
apy. For this purpose, we have devised the simplest mathematical model capable
of representing these protocols in a clear manner. More sophisticated multicom-
partment models including the evolution of resistance, combination therapy, toxic
side-effects and stochastic fluctuations can be developed in a straightforward way
using the present model as a starting point.
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Figure 7: Slightly sensitive tumors (ρ = 0.01 mg−1). Again, the fraction of cells that have
survived the treatment σi = P (tnad)/P (0) at the time tnad when the tumor reaches its minimum
size (nadir) is computed for each protocol pi. Then the same computation is repeated for a 300×
300 square grid of values in the parameter set (s, b). Finally, the relative destruction between two
protocols pi and pj is represented in the parameter space by computing the natural logarithm of
the quotient σi/σj (color bar). If log(σi/σj) > 0 in the color bar, the protocol pj is better than
protocol pi. (a) The effects of increasing the dose represented by σ1/σ2 are always beneficial. (b)
The case σ1/σ3 representing an increase in dose-density, which are barely beneficial. (c) Dose-
intensity versus dose-density is studied by computing σ3/σ2. As can be seen, dose intensification
is always a better strategy in this scenario. (d) Longer continuous infusions σ1/σ4 represents now
a very bad strategy.
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Our results demonstrate that dose-dense protocols should be generally benefi-
cial, specially if the Norton-Simon hypothesis stands. The main idea underlying
this hypothesis is that chemotherapy is less effective on slowly growing tumors. In
particular, if the rate of tumor growth decreases with tumor size, the rate of growth
just before a cycle of chemotherapy starts is lower than the rate of growth right
after it, and therefore regrowth might dominate, leading to unsuccessful treatment.
However, when most of the cancer cells are intrinsically insensitive to the drugs,
our results suggest that dose-density might be barely useful, compared to dose
escalation. As a rule of thumb, it can be said that dose-density should be more
helpful when cancer cells are very chemosensitive and the regrowth between cy-
cles is considerable, relative to the destruction caused by the cytotoxic drugs.
It is notable that our investigation insinuates that the unresponsiveness of a tu-
mor to chemotherapeutic drugs can be broadly classified into two categories. The
first could be termed intrinsic sensitivity, and depends on all types of biomolecular
mechanisms that a single tumor cell possess to circumvent the destructive effects
of a cytotoxic drug. In our model, this sensitivity is represented by the parameter
ρ, and leads to the concept of effective dose ρD, which was introduced in previous
works [12]. The second type of sensitivity could be termed extrinsic sensitivity,
which emerges as a consequence of how a tumor organizes as a whole and its
morphology. We believe that it is this second class of sensitivity that should be
linked to the Norton-Simon hypothesis and, consequently, the parameter s would
model an unresponsiveness of this nature.
To conclude, the results for highly sensitive tumors also point to the fact that
the optimal situation should be obtained when the regrowth between cycles is
avoided by increasing the duration of the infusions and administering drugs in an
almost continuous fashion. Since continuous protocols can be too toxic and lead
to tachyphylaxis, the present work indicates that perhaps other means of avoiding
regrowth between cycles should be devised, instead of increasing the frequency
of the protocol. For example, a good strategy could be to render the tumor cells
quiescent after chemotherapeutic drugs have caused their damage. This could
be achieved by means of some targeted cytostatic drug [12]. Then, hours after
the interruption of the cytostatic effects [41], the cells would abandon the G0
phase and reenter the cell cycle, to suffer another destructive wave of cytotoxic
chemotherapy.
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Figure 8: Logistic vs Gompertz. (a) A comparison between a logistic growth (red) given by
the equation γ(P ) = 0.8 P (1 − P/K) and a Gompertzian growth (blue) given by γ(P ) =
0.12 P log(K/P ). The initial condition is P0 = 1 cell, for both time series. The parameters
have been adjusted so that the time at which P = K/2 is the same. As can be seen, the logistic
growth is more steep. (b) The dose-intense protocol p
2
is compared to the dose-dense protocol
p
3
by computing σ3/σ2 for the Gompertz type of growth and following exactly the methods ex-
plained in the two previous figures. The color bar represents log(σ3/σ2), and it is positive when
the protocol p
2
is more effective than the protocol p
3
.
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